sellModerate cluster of 2
James F Oliviero III sold $64k of CKPT
CEO, President and Director at Checkpoint Therapeutics, Inc.. 19,564 shares at an average of $3.27, traded Feb 7, 2025, filed Feb 11, 2025.
Warning score
41Value
$64k
19,564 shares
Holdings after
3,775,019
-1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +8Trade size$64k at market
- 0Share of holdings soldSold 0.5% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-25-011656, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 7, 2025 | SOpen-market sale COMMON STOCK | -9,233 | $3.41 | $31k | 3,785,350 | Feb 11, 2025 |
| Feb 10, 2025 | SOpen-market sale COMMON STOCK | -10,331 | $3.15 | $33k | 3,775,019 | Feb 11, 2025 |
Related signals
Other insiders at Checkpoint Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | CKPTsell Checkpoint Therapeutics, Inc. | Fortress Biotech, Inc. owner | $129k 100,000 shares | -2% | |
| 37Weak | Checkpoint Therapeutics, Inc. | William Garrett Gray Chief Financial Officer | $50k 12,322 shares | -1% | |
| 40Moderate | Checkpoint Therapeutics, Inc. | James F Oliviero III CEO, President and Director | $61k 15,090 shares | -0% | |
| 43Moderate | Checkpoint Therapeutics, Inc. | William Garrett Gray Chief Financial Officer | $272k 74,110 shares | -5% | |
| 60Notable | Checkpoint Therapeutics, Inc. | William Garrett Gray Chief Financial Officer | $1.1M 268,432 shares | -21% | |
| 63Notable | Checkpoint Therapeutics, Inc. | James F Oliviero III CEO, President and Director | $3.1M 822,397 shares | -20% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.